(Q50775865)

English

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

scientific article published in April 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. (English)

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Cancer and Leukemia Group B

8

object named as

Cancer and Leukemia Group B

1 reference

Europe PubMed Central

19 March 2018

author name string

Gerald Clamon

1

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

James Herndon

2

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

Jeffrey Kern

3

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

Ramaswamy Govindan

4

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

Jennifer Garst

5

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

Dorothy Watson

6

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

Mark Green

7

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

language of work or name

0 references

publication date

1 April 2005

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

103

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

8

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

1670-1675

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

21 January 2018

Herceptest: HER2 expression and gene amplification in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring the clinical response. What does it mean?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

EGF receptor as a therapeutic target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability in patients receiving trastuzumab with or without chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20950

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20950

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

1 reference

Europe PubMed Central

19 March 2018

http://europepmc.org/abstract/MED/15751020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50775865&oldid=1561179640"